Form 4: Dianthus Therapeutics Chief Medical Officer Simrat Randhawa Reports Stock Option Grant

Simrat Randhawa, Chief Medical Officer of Dianthus Therapeutics, reports the acquisition of stock options.

Summary

• Simrat Randhawa, the Chief Medical Officer of Dianthus Therapeutics, Inc., filed a Form 4 on May 28, 2024, reporting a transaction that occurred on May 23, 2024.
• Randhawa acquired stock options for 100,000 shares of Dianthus Therapeutics common stock at an exercise price of $21.77.
• The options vest in equal monthly installments over four years, starting May 1, 2024, contingent upon continued service to the issuer.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future. The sentiment is neutral to positive.

Positives

• The grant of stock options aligns the Chief Medical Officer's interests with those of the shareholders, incentivizing performance and company growth.

Future Outlook

The vesting schedule of the stock options suggests a long-term commitment from the Chief Medical Officer to Dianthus Therapeutics.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with shareholder value.

Stakeholder Impact

• The stock option grant aligns management's interests with those of shareholders, potentially driving long-term value creation.

Key Dates